Post-authorisation Safety Study in Patients With Type 2 Diabetes to Assess the Risk of Liver Injury, Kidney Injury, Urinary Tract and Genital Infections, and Diabetic Ketoacidosis in Patients Treated With Empagliflozin, Compared to DPP-4 Inhibitors
Clinical trial NCT02864914 · COMPLETED
Trial details
- NCT number
- NCT02864914
- Sponsor
- Boehringer Ingelheim
- Status
- COMPLETED
- Study type
- OBSERVATIONAL
- Start date
- 2016-03-15
- Primary completion
- 2022-07-29
- Enrollment
- 333580
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.